Preparations for a late-stage AIS trial advanced, supported by strong Phase 2 data and favorable FDA-requested safety results. Cash reserves of $6.35 million provide four quarters of funding, with regulatory milestones and trial protocol finalization expected in Q3 CY2026.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.